TREATING HEART FAILURE AND VENTRICULAR ARRHYTHMIAS

• US 20090239940A1
• Filed: 02/23/2009
• Published: 09/24/2009
• Est. Priority Date: 07/22/1997
• Status: Abandoned Application

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Del Monte, Federica, Prunier, Fabrice, Hajjar, Roger J.
• Application Number:
  US12/391,257
• Publication Number:
  US 20090239940A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14171 Demonstrated in vivo effect

Abstract

The present invention provides methods and materials for treating heart disorders, including heart failure and arrhythmia, by enhancing SERCA2a activity. Heart cells in a subject can be treated, for example, by introducing, into the heart of the subject, an adeno-associated virus subtype 6 (AAV6) viral delivery system that includes a functional nucleic acid encoding SERCA2a. For example, the functional nucleic acid encodes a non-viral therapeutic protein, thereby treating the subject.

Claims

1. A method for treating arrhythmia in a subject with ischemic heart disease, comprising enhancing the function of SERCA2a, thereby treating the arrhythmia in the subject.

2. The method of claim 1, wherein enhancing the function of SERCA2a is achieved by administering to the subject a therapeutically effective amount of a recombinant expression vector encoding SERCA2a.

3. The method of claim 2, wherein the administration is local administration.

4. The method of claim 2, wherein the SERCA2a expression vector is administered to the heart of the subject by introducing the SERCA2a expression vector into one or more coronary vessels.

5. The method of claim 2, wherein the SERCA2a expression vector is administered to the heart of the subject by introducing the SERCA2a expression vector into one or more coronary vessels by percutaneous anterograde myocardial gene transfer.

6. The method of claim 1, wherein enhancing the function of SERCA2a is achieved by administering a therapeutically effective amount of an agent that increases SERCA2a function.

7. The method of claim 6, wherein the agent that increases SERCA2a function is selected from the group consisting of a compound that increases the activity of SERCA2a, a compound that decreases the activity of phospholamban, or an inhibitory RNA of phospholamban.

8. The method of claim 1, wherein the arrhythmia is a reperfusion-induced arrhythmia.

9. The method of claim 1, wherein the arrhythmia is a ventricular tachyarrhythmia.

10. The method of claim 9, wherein the tachyarrhythmia is triggered by acute myocardial ischemia.

11. The method of claim 9, wherein the tachyarrhythmia is triggered by reperfusion.

12. The method of claim 1, wherein the arrhythmia is a ventricular tachyarrhythmia which results from a previously formed myocardial infarction scar and wherein the subject is without active myocardial ischemia.

13. The method of claim 1, wherein the arrhythmia is a tachyarrhythmia or bradyarrythmia.

14. The method of claim 1, wherein the arrhythmia is of an atrial, junctional, atro-ventricular or ventricular origin.

15. The method of claim 1, wherein the vector is a DNA or RNA viral vector.

16. The method of claim 15, wherein the vector is an adenovirus, adeno-associated virus, or lentivirus vector.

17. The method of claim 16, wherein the vector is AAV-6.

18. The method of claim 5, wherein the agent is administered using a stent.

19. A method for protecting against tissue damage or death caused by reperfusion-induced arrhythmia in a subject with acute myocardial ischemia comprising enhancing the function of SERCA2a, thereby protecting against tissue damage or death.

20. The method of claim 19, wherein enhancing the function of SERCA2a is achieved by administering to the heart of the subject at the time of reperfusion or prior to onset of the acute myocardial ischemia, a therapeutically effective amount of a recombinant expression vector encoding SERCA2a.

21. The method of claim 20, wherein the SERCA2a expression vector is administered to the heart of the subject by introducing the SERCA2a expression vector into one or more coronary vessels.

22. The method of claim 21, wherein the administering is local administration.

23. The method of claim 20, wherein the SERCA2a expression vector is administered to the heart of the subject by introducing the SERCA2a expression vector into one or more coronary vessels by percutaneous anterograde myocardial gene transfer.

24. The method of claim 20, wherein the SERCA2a expression vector is administered to the heart of the subject by introducing the SERCA2a expression vector directly into the myocardium.

25. The method of claim 20, wherein the step of enhancing the function of SERCA2a is achieved by administering a therapeutically effective amount of an agent that increases SERCA2a function.

26. The method of claim 25, wherein the agent that enhances SERCA2a function is selected from the group consisting of a compound that enhances the activity of SERCA2a, a compound that decreases the activity of phospholamban, or an inhibitory RNA of phospholamban.

27. The method of claim 19, wherein the reperfusion-induced arrhythmia is a ventricular tachyarrhythmia or ventricular bradyarrythmia.

28. The method of claim 19, wherein the reperfusion-induced arrhythmia is of an atrial, junctional, atro-ventricular or ventricular origin.

29. The method of claim 19, wherein the recombinant expression vector is an adenovirus, adeno-associated virus, or lentivirus vector.

30. The method of claim 29, wherein the recombinant expression vector is AAV-6.

31. The method of claim 25, wherein the agent is administered using a stent.

32. A method for reducing risk of death or injury due to arrhythmia in a subject with ischemic heart disease, comprising:

occluding a coronary artery and a coronary vein with a first and second angioplasty balloon, respectively, thereby restricting the flow of blood through the coronary vessels;

injecting through the lumen of the first angioplasty balloon into the lumen of the coronary artery a recombinant expression vector encoding SERCA2a, thereby causing the vector to perfuse the myocardium, wherein the vector thereafter expresses the SERCA2a in the myocardium, thereby reducing risk of death or injury due to arrhythmia in a subject with ischemic heart disease.

33. The method of claim 32, wherein the arrhythmia is a reperfusion-induced arrhythmia.

34. The method of claim 32, wherein the arrhythmia is a ventricular tachyarrhythmia.

35. The method of claim 34, wherein the tachyarrhythmia is triggered by acute myocardial ischemia.

36. The method of claim 34, wherein the tachyarrhythmia is triggered by reperfusion.

37. The method of claim 32, wherein the arrhythmia is a tachyarrhythmia or bradyarrythmia.

38. The method of claim 32, wherein the arrhythmia is of an atrial, junctional, atro-ventricular or ventricular origin.

39. The method of claim 32, wherein the recombinant expression vector is an adenovirus, an adeno-associated virus, or a lentivirus vector.

40. The method of claim 39, wherein the recombinant expression vector is AAV-6.

41. The method of claim 32, wherein the recombinant expression vector comprises a myocardial-specific promoter that is operably linked to a nucleic acid encoding SERCA2a.

42. The method of claim 32, wherein the coronary artery is the left anterior descending artery (LAD) or the distal circumflex artery (LCX), and coronary vein is the great coronary vein (GCV), the middle cardiac vein (MCV), or the anterior interventricular vein (AIV).

43. The method of claim 32, wherein the step of injecting the vector through the lumen occurs after ischemic preconditioning of the coronary vessels.

44. The method of claim 32, wherein the step restricting the flow through the coronary vessels is for a period of about 30 seconds to 5 minutes.

45. The method of claim 43, wherein the step of ischemic preconditioning is for a period of about 1 to 4 minutes.

46. The method of claim 32, wherein the subject is a human.